Clinical Study of Ralitrexed plus Oxaliplatin versus Fluorouracil and Leucovorin plus Oxaliplatin for Advanced Colorectal Cancer

Objective To evaluate the efficacy and toxicity of oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil and leueovorin for patients with advanced colorectal cancer.Methods 58 patients with advanced colorectal cancer were divided into 2 groups: Group oxaliplatin + raltitrexed with 28 patients(raltitrexed 3 mg / m2ivgtt,d1;oxaliplatin 130 mg / m2ivgtt,d1.3 weeks a cycle) and Group oxaliplatin + leueovorin + fluorouracil with 30 patients(leucovorin 200 mg / m2ivgtt,d1 ～ d5;fluorouraeil 375 mg / m2ivgtt,d1 ～ d3;oxaliplatin 130 mg / m2ivgtt,d1.3 weeks a cycle).Results In Group oxaliplatin + raltitrexed and Group oxaliplatin + leueovorin + fluorouracil,the response rate was 28.6% and 16.7%(P = 0.277),the disease control rate was 71.4% and 70.0%(P 0.05),the median time to progress was 8.4 months and 6.9 months(P = 0.049),respectively.Main side effects of both groups were vomiting,neutrocytopenia,thrombocyto-penia,nausea,fever and infection,which were comparable between the 2 groups(P 0.05).Conclusion The benefit of oxaliplatin plus raltitrexed regimen is over oxaliplatin plus leueovorin and fluorouracil in the time to progress in patients with advanced colorectal cancer.These results indicate that further clinical study is of great value.